A total of six clinical trials involving patients with BC have been conducted; the different inhibitors of indoleamine 2,3 dioxygenase 1 examined were epacadostat, indoximod, and navoximod/GDC-0919 [134]. This evidence concerns the gene IDO1 and breast cancer.